 |
 |
| Teikoku Seiyaku’s medicated patches and plasters are currently sold in more than 40 countries worldwide.
Lidoderm®, an analgesic plaster for the treatment of post-herpetic neuralgia (PHN) first approved for prescription
use in the US, has been marketed by Endo Pharmaceuticals in the US. The equivalent product to Lidoderm® for
Europe, the Middle East and South America are marketed by Grünenthal and others, and the one for Asia is
marketed by Mundipharma and others. |
|
|
 |
|
| Our subsidiaries in the US conduct post-marketing surveillance and disseminate information about
Teikoku Seiyaku. The US subsidiary takes full advantage of its location in Silicon Valley, home to scientists and
professionals from all over the world, to conduct dynamic research programs. In addition, we acquired a product
license from the companies in Denmark and France, obtained approval in Japan, and market the products to
healthcare organizations in Japan through our sales partners. |
|
